Outcomes of Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: A Contemporary Series From the Bladder Cancer Research Consortium

Shariat, Shahrokh F.; Karakiewicz, Pierre I.; Palapattu, Ganesh S.; Lotan, Yair; Rogers, Craig G.; Amiel, Gilad E.; Vazina, Amnon; Gupta, Amit; Bastian, Patrick J.; Sagalowsky, Arthur I.; Schoenberg, Mark; Lerner, Seth P.

doi:10.1016/j.juro.2006.08.004

Cited by 595 publications

(410 citation statements)

References 19 publications

Supporting

Mentioning

365

Contrasting

Unclassified

Order By: Relevance

“…3 From the present study it was noticed that most of the patients (16 patients, 61.54% ) had tumors with grade III ( 5 patients ,19.23 %) had tumors with grade II, and (5 patients,19.23%) had grade I, However our data was close to Rodel et al 23 where high grade tumors represented 57.8% only, 23 However, that was different from Zietman et al 20 who found that high grade tumors represent 77.7%, and also different from Zapatero et al, 22 who reported that 94% of the tumors were of high grade. 20,22 The present study showed that 9 patients (34.61 %) had T3 disease, while T2 disease was seen in 8 patients (30.77%), 7patients (26.9%) had T4 disease and 2 patients (7.69%) with T1 disease stage, this result is consistent with the disease stage reported by Shariat et al 25 who noticed that most of the patients (36,5%) had T3 disease, but different in the percent of other patient disease stages. However, this was different from the disease stage reported by Kaufman et al 26 where T2 disease constituted 88% and T3 disease constituted 12% of the entire patient population.…”

supporting

confidence: 92%

The Relation between Survivin Gene Expression and Urinary Bladder Cancer Disease

Arafat¹,

Ashry²,

Alrazek³

et al. 2017

HPMIJ

View full text Add to dashboard Cite

Purpose: The aim of this study is to investigate the expression of survivin gene in patients suffering from urinary bladder cancer, thus contributing to further understanding of the molecular etiology of the disease by assessment of Survivin gene expression on both RNA and protein levels in urinary bladder tissue samples and Correlate between its expression and pathological prognostic parameters of patients with urinary bladder cancer risk. Methods:In the present study 26 cases of urinary bladder cancer and 26 cases of normal tissues far from tumor sites in the urinary bladder of the same patients (as control samples) were collected, also 10 paraffin-embedded tissue samples from consecutive of archival bladder specimens patients and 10 tissue samples that of healthy tissue from the same individual as control group were collected for immunohistochemical detection of survivin protein and real time PCR for survivin mRNA detection. Results:In normal tissues of control samples no expression for survivin gene has been noticed. However, in patients affected with bladder cancer the survivin expression was highly increased by increasing degree of tumor malignancy as indicated by real time PCR for survivin mRNA and immunohistochemistry for survivin protein. Conclusion:From this study, it is concluded that survivin protein was not expressed in normal bladder urothelium but was present in a high percentage in tissue samples of patients suffering from bladder cancer and its expression is associated with disease recurrence, tumor grade, progression and mortality. Hospice and Palliative Medicine International Journal Research Article Open AccessThe relation between survivin gene expression and urinary bladder cancer disease ii. Samples that used to detect mRNA expression levels: Tissue samples were taken from tumor masses from urinary bladder tissues (26 tumor samples) and normal tissues far from tumor sites in the urinary bladder as control samples (26 control samples from the same patients) . All samples were stored at (-80°C) until they are used.iii. Samples that used for protein expression detection: 10 paraffin-embedded tissue samples from consecutive of archival bladder specimens patients, also 10 tissue samples that of healthy tissues from the same individuals as control group.Immunohistochemical staining for survivin was done using the procedure (According to: Buchwalow and Bocher, 2010) and Immunohistochemical staining protocol (Genemed, USA):The list of reagents used for Immunohistochemical staining and mRNA extraction process could be found in (Table 1). ii. Different concentration of ethyl alcohol (30%, 50%, 70%, 80%, 90%, 95% and100%).iii. Xylene .iv. Paraffin wax. ii. Survivin reverse primer : 5΄CAA CCG GAC GAA TGC TTT T 3΄iii. Survivin probe: 5΄ CCA GAT GAC GAC CCC ATA GAG GAA CA 3΄ labeled by VIC® as a reporter dye on the 5´ end and TAMRA™ as a quencher dye on the 3´ end.iv. TaqMan Universal PCR Master Mix (Applied Biosystems, USA).The procedure included i. Fixation of tissues in 10% neutral buffered fo...

show abstract

supporting

confidence: 92%

The Relation between Survivin Gene Expression and Urinary Bladder Cancer Disease

Arafat¹,

Ashry²,

Alrazek³

et al. 2017

HPMIJ

View full text Add to dashboard Cite

show abstract

“…20 The 2002 TNM classification was used for pathologic staging, and the 1973 WHO classification for pathologic grading. To ensure validity of the data extraction, two clinicians read pathology reports of 162 consecutive cystectomy patients, whereas blinded to patient clinical parameters and the finding of the other reviewer.…”

Section: Pathologymentioning

confidence: 99%

Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness

et al. 2007

Self Cite

View full text Add to dashboard Cite

The aim of this study was to evaluate the association between p53, p21, p27 and Rb expression, alone or in combination, with pathological features and clinical outcomes of urothelial carcinoma of the bladder. Immunohistochemical staining for p53, p21, p27 and pRB was performed on tissue microarrays comprising normal urothelium from nine controls, transurethral resection specimens from 74 patients with Ta, Tis and/or T1 bladder urothelial carcinoma, radical cystectomy specimens from 226 consecutive urothelial carcinoma patients, and lymph nodes with tumor invasion from 50 of the 226 cystectomy patients. All nine controls had normal status of biomarkers. The proportion of biomarkers alterations was highest in lymph node metastases. p53, pRB and p27 were associated with pathologic stage, lymphovascular invasion and lymph node metastases (P-valuesr0.050). Each biomarker alone, each combination of two biomarkers and the number of altered biomarkers were all independently associated with disease recurrence and bladder cancer-specific death (Pvaluesr0.046). In patients with organ-confined disease, p53, p21 and p27 were independently associated with disease recurrence and bladder cancer-specific death (P-valuesr0.046). There was a good but not perfect concordance in the expression of biomarkers between matched transurethral resection and cystectomy specimens (n ¼ 22; concordance rates: 77-86%) and between matched lymph node and cystectomy specimens (n ¼ 50, 70-92%). In conclusion, p53, p21, p27 and pRB have a cooperative/synergistic role in the biologic behavior of bladder urothelial carcinoma. In contrast to the use of single biological markers, evaluation of their combined status may improve prognostic models and help identify patients who might benefit from adjuvant therapies and in decision-making. Modern Pathology (2007) 20, 445-459.

show abstract

“…Up to 50% of these patients will harbour metastases. 2,3 Radical cystectomy (RC) and bilateral pelvic lymph node dissection (PLND) have become the standard treatment option over the past 30 years with 30-day overall mortality of 1.5% to 2% and morbidity ranging from 30% to 64%. 2,4 All major publications of RC series include patients treated prior to 2005.…”

Section: Introductionmentioning

confidence: 99%

Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort

Power

Kassouf

Bell

et al. 2012

CUAJ

View full text Add to dashboard Cite

Background: The present study documents the natural history and outcomes of high-risk bladder cancer after radical cystectomy (RC) in patients who did not receive neoadjuvant chemotherapy during a contemporary time period. Methods: We analyzed 1180 patients from 1993 to 2008 with >pT3N0 or pT0-4N+ bladder cancer who underwent RC ± standard (sLND) or extended (eLND) lymph node dissection from 8 Canadian centres. Results: Of the 1180 patients, 55% (n = 643) underwent sLND, 34% (n = 402) underwent ePLND and 11% did not undergo a formal LND. Of the total number of patients, 321 (27%) received adjuvant chemotherapy. The median follow-up was 2.1 years (range: 0.6 to 12.9). Overall 30-day mortality was 3.2%. Clinical and pathological stages T3-4 were present in 6.1% and 86.7% of the patients, respectively; this demonstrates a dramatic understaging. Overall survival (OS) at 2 and 5 years was 60% and 43%, respectively. Patients who received adjuvant chemotherapy had a 2-and 5-year disease-specific survival (DSS) of 72% and 57% versus 64% and 51% for those who did not (log-rank p = 0.0039). The 2-and 5-year OS for high-risk node-negative disease was 67% and 52%, respectively, whereas for node-positive patients, the OS was 52% and 32%, respectively (p < 0.001). The OS, DSS and RFS for patients with pN0 were significantly improved compared to those who did not undergo a LND (log-rank p = 0.0035, 0.0241 and 0.0383, respectively). Interpretation: This series suggests that bladder cancer outcomes in advanced disease have improved in the modern era. The need for improved staging investigations, use of neoadjuvant chemotherapy and performance of complete LND is emphasized.

show abstract

Outcomes of Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: A Contemporary Series From the Bladder Cancer Research Consortium

Abstract: The results of this large, contemporary, multi-institutional series show that radical cystectomy and pelvic lymphadenectomy provide durable local control and disease specific survival in patients with localized invasive transitional cell carcinoma.

Cited by 595 publications

References 19 publications

The Relation between Survivin Gene Expression and Urinary Bladder Cancer Disease

The Relation between Survivin Gene Expression and Urinary Bladder Cancer Disease

Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness

Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort

Contact Info

Product

Resources

About